Takeda Pharmaceutical Co Ltd ADR
NYSE: TAK · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Updated 2026-06-05
Takeda Pharmaceutical Co Ltd ADR (TAK) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.07T | $2.85T | $2.76T | $2.82T | $2.79T | $3.58T | $3.96T | $4.57T | $4.30T | $3.82T | $4.36T | $4.11T | $13.87T | $12.82T | $12.91T | $13.18T | $13.96T | $15.11T | $14.25T | $15.52T |
| Cash & equivalents | $1.65T | $1.61T | $229.53B | $266.54B | $217.90B | $454.25B | $289.61B | $666.05B | $652.15B | $451.43B | $319.45B | $294.52B | $702.09B | $637.61B | $966.22B | $849.70B | $533.53B | $457.80B | $385.11B | $597.63B |
| Current assets | $2.36T | $2.24T | $1.48T | $1.57T | $1.59T | $1.28T | $1.46T | $1.59T | $1.52T | $1.37T | $1.26T | $1.08T | $3.05T | $2.47T | $2.71T | $2.59T | $2.40T | $2.56T | $2.52T | $3.10T |
| Total liabilities | $611.38B | $526.75B | $706.35B | $658.53B | $649.75B | $1.51T | $1.73T | $2.03T | $2.09T | $1.81T | $2.41T | $2.09T | $8.71T | $8.09T | $7.74T | $7.49T | $7.60T | $7.83T | $7.31T | $7.71T |
| Current liabilities | $442.41B | $428.71B | $472.11B | $428.48B | $436.60B | $751.73B | $613.63B | $802.75B | $1.02T | $857.21B | $1.37T | $737.51B | $2.51T | $2.18T | $1.77T | $2.15T | $2.48T | $2.31T | $2.51T | $2.44T |
| Long-term debt | — | — | — | — | — | — | — | — | $5.24B | $0.00 | $599.86B | $985.64B | $4.77T | $4.51T | $4.61T | $4.14T | $4.04T | $4.48T | $3.97T | — |
| Shareholder equity | $2.42T | $2.28T | $2.01T | $2.12T | $2.09T | $2.01T | $2.16T | $2.47T | $2.14T | $1.95T | $1.89T | $2.00T | $5.16T | $4.72T | $5.17T | $5.68T | $6.35T | $7.27T | $6.94T | $7.81T |
| Retained earnings | $2.30T | $2.52T | $2.01T | $2.17T | $2.27T | $2.25T | $2.24T | $1.90T | $1.60T | $1.52T | $1.51T | $1.56T | $1.57T | $1.37T | $1.51T | $1.48T | $1.54T | $1.39T | $1.19T | $1.06T |
| Accounts receivable | $400.66B | $388.25B | $301.45B | $279.70B | $283.59B | $361.87B | $387.02B | $442.66B | $466.83B | $430.57B | $444.78B | $428.79B | $749.12B | $784.92B | $812.71B | $724.38B | $681.69B | $697.61B | $725.25B | $880.15B |
| Inventory | $105.31B | $116.13B | $131.66B | $137.70B | $137.13B | $195.01B | $229.53B | $254.33B | $262.35B | $254.01B | $226.29B | $212.94B | $986.74B | $759.60B | $753.88B | $853.17B | $986.46B | $1.21T | $1.22T | $1.40T |
| Goodwill | — | — | $284.45B | $256.12B | $217.12B | $582.26B | $675.35B | $814.67B | $821.91B | $779.32B | $1.02T | $1.03T | $4.16T | $4.01T | $4.03T | $4.41T | $4.79T | $5.41T | $5.32T | $5.83T |
Frequently asked questions
What is Takeda Pharmaceutical Co Ltd ADR's revenue?
Takeda Pharmaceutical Co Ltd ADR's trailing twelve-month revenue is $4.51T, and consensus projects about $5.89T by 2030. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is TAK?
In its most recent fiscal year, TAK ran a gross margin of 51.06%, an operating margin of 11.99%, and a net margin of 4.26%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does TAK generate?
TAK produced $808.70B in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is TAK's balance sheet healthy?
TAK holds $597.63B in cash and equivalents against — in long-term debt, on $7.81T of shareholder equity. That debt is best read against the cash flow the business throws off each year.